Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its lead product candidate, APR-246, is a small molecule p53 reactivator that is being developed for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). APR-246 product candidate is designed to be administered intravenously and forms the active moiety, 2-methylene-quinuclidin-3-one (MQ), under physiological conditions. Its second product candidate, APR-548, is a p53 reactivator. APR-548 is being developed in an oral dosage form.